Boston Scientific

BSX

Market cap $114B

New York, New York--(Newsfile Corp. - March 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Boston Scientific Corporation ("Boston Scientific Corporation") (NYSE: BSX) concerning potential violations of the federal securities laws. On February 4, 2026, Boston Scientific reported fourth-quarter 2025 results.

The latest trading day saw Boston Scientific (BSX) settling at $76.85, representing a +1.45% change from its previous close.

NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Boston Scientific (BSX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

ALAMEDA, Calif., Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2025.

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

New York, New York--(Newsfile Corp. - February 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Boston Scientific Corporation ("Boston Scientific Corporation") (NYSE:BSX) concerning potential violations of the federal securities laws. On February 4, 2026, Boston Scientific reported fourth-quarter 2025 results.

MARLBOROUGH, Mass., Feb. 23, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Cathy Smith and Christophe Weber to its Board of Directors, effective February 18, 2026.

Abbott edges out Boston Scientific in the MedTech faceoff, with valuation appeal, strong CGM momentum and strategic deals boosting its investment case.

New York, New York--(Newsfile Corp. - February 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Boston Scientific Corporation ("Boston Scientific Corporation") (NYSE: BSX) concerning potential violations of the federal securities laws. On February 4, 2026, Boston Scientific reported fourth-quarter 2025 results.